Application — Cortical surface
Beinao-1 GCP multi-center registration trial (2026)
Device
Lab or organization
Beinao-1 GCP registration trial (2026)
The registered multi-center trial of Beinao-1, the wireless semi-invasive BCI from CIBR and NeuCyber. Facts are as published by the cited sources. Implant counts from the earlier investigator-initiated phase disagree between sources; those counts stay on the device sheet.
Trial facts
| Field | Value and source scope |
|---|---|
| Registered status | Entered registered clinical trials in 2026 [1, 4] |
| Trial start | March 31, 2026, with the first two trial implants the same day at Tiantan Hospital and Xuanwu Hospital [1, 2, 3] |
| Design | GCP-compliant, multi-center [1] |
| Initial participants | Two spinal cord injury patients [1] |
| Registration indication | High paraplegia (tetraplegia) per Beijing News [2] |
| Planned enrollment | 36 patients initially [1, 3]; NeuCyber told Reuters it hopes to expand to 50 (company statement) [5] |
| Follow-up | 26 weeks per Xuanwu Hospital [3] |
| Registry identifier | No ChiCTR or ClinicalTrials.gov identifier found in the sources used here |
| Reported timeline | CIBR’s director: 30 to 40 patients within 2026 and NMPA registration filing in 2027 (institute statement) [2]; NeuCyber: commercial availability two to three years out (company statement) [5] |
| Safety | Xuanwu Hospital reports no serious adverse events [3]; no adverse-event dataset published |
Primary sources
- CIBR. “Beinao No. 1” Advances to GCP Clinical Trials. April 2026.
- Beijing News via Sina (Chinese). Beinao-1 completes 10 implants. 20 April 2026.
- Xuanwu Hospital (Chinese). First GCP implant. 2 April 2026.
- China Daily. China’s Beinao-1 brain-computer interface enters registered trials. 15 Jun 2026.
- Reuters. Beijing-backed brain chip firm says it is 3 years behind Musk’s Neuralink. 20 Mar 2026.